Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

EARLY_PHASE1

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-01

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist

NCT06500429

Overweight and Obesity Healthy

COMPLETED PHASE2

Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

NCT05786521

Aging Diabetes Mellitus, Type 2 PreDiabetes +1 more

COMPLETED PHASE4

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06124807

Obesity Overweight and Obesity

COMPLETED PHASE2

A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

NCT07184632

Overweight Obesity

RECRUITING PHASE2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

NCT06143956

Obesity Overweight

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants will be assigned to one of three groups: 1) control, 2) microdosed sublingual semaglutide, 3) microdosed subcutaneous semaglutide. At baseline and every 4 weeks thereafter, participants will be asked to complete surveys on health, wellness, mood, demographic information, and similar. Additionally, at baseline and every 12 weeks thereafter, they will be requested to complete evaluative blood work to measure CBC, CMP, and standard health biomarker panels (e.g., cholesterol, glucose, creatinine, sodium, potassium). From baseline throughout the duration of the study, participants will be given the option to share data from wearable activity and health trackers with the research team for greater accuracy in evaluating measures of activity, sleep, heart rate, and similar.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Longevity Quality of Life Mood Inflammation Immune Health Pain Management Weight Management Alertness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Single-Center, Prospective, Blinded, Randomised, Controlled Trial

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral Placebo

Placebo administered in PCCA sub-magna compounding base only.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Sublingual Placebo (weekly) for up to 6 months

Sublingual GLP1

Semaglutide 1mg/1ml administered in PCCA sub-magna compounding base only.

Group Type ACTIVE_COMPARATOR

GLP-1

Intervention Type DRUG

Sublingual GLP1 (weekly), Subcutaneous GLP1 (weekly), Sublingual Placebo (weekly) for up to 6 months.

Subcutaneous GLP1

Semaglutide 1mg/ml x5ml

Group Type ACTIVE_COMPARATOR

GLP-1

Intervention Type DRUG

Sublingual GLP1 (weekly), Subcutaneous GLP1 (weekly), Sublingual Placebo (weekly) for up to 6 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GLP-1

Sublingual GLP1 (weekly), Subcutaneous GLP1 (weekly), Sublingual Placebo (weekly) for up to 6 months.

Intervention Type DRUG

Placebo

Sublingual Placebo (weekly) for up to 6 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Semaglutide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* New or existing AgelessRx patient
* Adults (aged 18-65)
* Any sex
* Any ethnicity
* BMI ≥ 20 kg/m\^2
* Interest in taking microdoses of semaglutide for health and longevity improvement with no intent to seek weight loss improvement.

Exclusion Criteria

* Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s)
* History of bariatric surgery
* Use of other weight-loss medications currently or within the past 6 months
* Contraindications to semaglutide
* Significant psychiatric illness that may affect participation
* Pregnant or breastfeeding individuals

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes